A phase 2, multicenter study to evaluate the efficacy and safety of using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma

Amir Jazaeri1, Robert Edwards2, Emese Zsiró3, Robert Brown4, Igor Gorbachevsky4, San Suzuki4, Maria Farids4, Robert Wenham4

1University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA; 3Roswell Park Cancer Institute, Buffalo, NY, USA; 4Iovance Biotherapeutics, San Carlos, CA, USA; 5 Moffitt Cancer Center, Tampa, FL, USA

BACKGROUND
- Cervical cancer is a leading cause of cancer-related death in women with over 12,000 new cases and 4,000 deaths in the US alone.1,2,3
- Advanced recurrent/persistent and metastatic forms of cervical cancer have poor outcomes with mean progression free survival (PFS) rates less than 6 months following standard platinum-based chemotherapy.4,5
- ORR remains below 11% and PFS of 6 months of less than 24% in patients who have failed at least 1 systemic therapy for their recurrent, metastatic, or persistent cervical carcinoma.6
- The presence of tumor-infiltrating lymphocytes (TIL) have been well documented in patients with HPV-associated cancers, including cervical carcinoma, and have been positively correlated with improved patient outcomes.7,8
- Several early studies have demonstrated the feasibility of isolation and culture of TIL from cervical tumors.9,10
- A pilot study of TIL therapy in 9 patients with previously treated cervical carcinoma demonstrated an ORR of 33% that included 2 durable long-term (46 and 54 mos) responses.11,12
- This study was designed to evaluate the efficacy and safety of LN-145, an autologous investigational TIL therapy for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma.

STUDY OVERVIEW
- Phase 2, multicenter prospective, open label, interventional study was designed to evaluate adoptive cell therapy (ACT) with autologous TIL infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical cancer who were unresponsive to or failing prior therapy.
- All squamous cell carcinoma, adenocarcinoma, and adenosquamous pathologies will be enrolled regardless of HPV status.
- Up to 40 clinical study sites globally
- This study aims to assess the potential of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma using the objective response rate (ORR).
- To characterize the safety profile of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma.
- To evaluate efficacy of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma using the objective response rate (ORR).
- To explore the potential of LN-145 and immune correlates of response, survival, toxicity of the treatment.
- To explore efficacy based on immune-related RECIST (irRECIST) as assessed by independent review.
- To assess health-related quality of life (HRQoL).

OBJECTIVES

Primary objective:
- To evaluate the efficacy of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma.

Secondary objective:
- To characterize the safety profile of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma.
- To evaluate efficacy of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma using the objective response rate (ORR).

Exploratory objective:
- To explore the potential of LN-145 and immune correlates of response, survival, toxicity of the treatment.
- To explore efficacy based on immune-related RECIST (irRECIST) as assessed by independent review.
- To assess health-related quality of life (HRQoL).

MAJOR INCLUSION CRITERIA
- 18 years of age or older;
- Must have metastatic, recurrent, or persistent cervical carcinoma not amenable to curative surgery or radiation;
- Must have at least 1 lesion resectable for TIL generation that yields at least 1.5 cm in diameter of tissue. If previously irradiated, the irradiation must have occurred at least 3 months prior to resection;
- Must have a remaining lesion measurable as per RECIST 1.1 for response assessment. If previously irradiated, the irradiation must have occurred at least 3 months prior to enrollment (tumor resection);
- Minimum 28 day washout from last dose of prior therapy;
- Prior cell transfer therapy;
- Systemic steroid therapy greater than 10mg daily equivalents of prednisone;
- Greater than grade 1 prior treatment-related toxicities except for peripheral neuropathy, alopecia, or vitiligo;
- Active immunotherapy-related grade 2 diarrhea or colitis in the previous 6 months; patients may be included if asymptomatic and demonstrated unifamilial colon by colonoscopy;
- Active systemic infections, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune system that, in the opinion of the investigator, would increase the risk of participation;
- Symptomatic and/or untreated brain metastases;
- Primary or acquired immunodeficiency;
- End-stage renal disease requiring dialysis;
- Left ventricular ejection fraction < 45%;
- Forced expiratory volume in one second ≤ 60% predicted;
- Primary malignancy in the previous 3 years requiring treatment in the last year; and
- Pregnant or breastfeeding.

MAJOR EXCLUSION CRITERIA
- Recurrent, metastatic, or persistent cervical carcinoma presents a high unmet medical need with low survival rates and with limited effective treatment options;
- Presence of TIL have been correlated with improved outcomes in cervical carcinoma;
- TIL have demonstrated efficacy in other solid tumors including durable long-term responses following progression on checkpoint inhibitors.
- Pilot data using TIL therapy for the treatment of cervical carcinoma has the potential for long-term durable responses.
- This study aims to assess the potential of TIL therapy for the treatment of cervical cancer patients with recurrent, metastatic, or persistent disease.

REFERENCES